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A 67-year-old man presented with bone pain, fatigue, weight loss, and dyspnea.   A blood 
count showed mild normocytic anemia (hemoglobin concentration 114 g/L) with normal 
leukocyte and platelet counts.  The erythrocyte sedimentation rate was elevated at 136 
mm/hour as was C-reactive protein at 40 mg/L.  Biochemical studies showed normal calcium 
and phosphate but minor elevation in alkaline phosphatase (156 U/L).  Long bone 
radiographs demonstrated diffuse cortical thickening and sclerosis of the distal femora. A 
Positron Emission Tomography/Computed Tomography scan showed intense 18F-
fluorodeoxyglucose uptake in the distal femora and proximal tibiae (bottom, left and 
centre). Bone sclerosis was apparent in the distal femora (bottom, right).  A core biopsy of 
the left distal femur demonstrated marked expansion and irregularity of the bone 
trabeculae (top left).  Normal hematopoiesis was virtually absent with a significant infiltrate 
of foamy histiocytes evident on hematoxylin and eosin staining (top centre).  Reticulin 
staining demonstrated focal fibrosis surrounding the abnormal histiocytes (top right).  
Further immunohistochemical staining showed the histiocytes to be positive for CD68R and 
factor XIIIA but negative for S100 and CD1a.  Next generation sequencing performed on 
bone marrow material detected a sequence variant c.1799T>A p.(Val600Glu) in codon 600 
of the BRAF gene.  The radiological and histopathological features, along with the presence 
of a BRAFV600E mutation, were diagnostic of Erdheim–Chester disease (ECD).    
 
ECD is a rare neoplastic disorder characterized by infiltration of multiple tissues by foamy 
CD68+CD1a− histiocytes.  The disease can have protean manifestations but, most 
characteristically, long-bone pain and osteosclerosis.  Recently, mutations activating the 
MAPK pathway have been found in more than 80% of patients with ECD, mainly BRAFV600E. 
This condition is related to Langerhans cell histiocytosis, which is characterized by the same 
mutation.  Treatment traditionally involved interferon-alpha, corticosteroids, and 
sometimes cytotoxic chemotherapy but more recently BRAF inhibitors, such as 
vemurafenib, have been shown to induce frequent durable responses.  
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